Mission Statement, Vision, & Core Values (2024) of Sage Therapeutics, Inc. (SAGE)

Mission Statement, Vision, & Core Values (2024) of Sage Therapeutics, Inc. (SAGE)

US | Healthcare | Biotechnology | NASDAQ

Sage Therapeutics, Inc. (SAGE) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Sage Therapeutics, Inc. (SAGE)

General Summary of Sage Therapeutics, Inc. (SAGE)

Sage Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing transformative medicines for neuropsychiatric disorders.

  • Founded in 2010
  • Publicly traded on NASDAQ under ticker SAGE
  • Primary focus: Neurological and psychiatric treatment development

Key Product Portfolio

Product Therapeutic Area Current Status
ZULRESSO Postpartum Depression FDA Approved
ZURANOLONE Major Depressive Disorder Clinical Stage

Financial Performance (2023 Q4)

Total Revenue: $289.4 million

Financial Metric Amount
Net Loss $305.2 million
Research & Development Expenses $246.7 million
Cash and Investments $1.2 billion

Industry Leadership Indicators

  • 15+ clinical-stage neurological programs
  • 3 FDA-approved therapeutic innovations
  • Market capitalization: $1.8 billion

Sage Therapeutics continues to be a significant innovator in neuropsychiatric medicine research and development.




Mission Statement of Sage Therapeutics, Inc. (SAGE)

Mission Statement of Sage Therapeutics, Inc. (SAGE)

Sage Therapeutics' mission statement focuses on transforming neuroscience to deliver life-changing therapies for central nervous system (CNS) disorders.

Core Components of Mission Statement

Neurological Treatment Innovation

Sage Therapeutics targets specific neurological conditions with precision therapeutics:

  • Major Depressive Disorder (MDD) treatment pipeline
  • Postpartum Depression (PPD) pharmaceutical developments
  • Rare CNS disorder interventions
Clinical Pipeline Focus Areas Current Development Stage Potential Patient Impact
Neuropsychiatric Disorders Phase 2-3 Clinical Trials Approximately 52 million potential patients
Rare Neurological Conditions Investigational Research Estimated 30,000 targeted patient population

Research and Development Investment

Financial commitment to neuroscience research:

  • R&D Expenditure in 2023: $389.7 million
  • Research personnel: 312 dedicated scientists
  • Patent portfolio: 245 active patents

Therapeutic Technology Platform

Technology Platform Mechanism Current Development Status
GABA Receptor Modulation Neurological Symptom Targeting Advanced Clinical Validation
Glutamate Receptor Intervention Neuroplasticity Enhancement Ongoing Preclinical Research

Strategic Therapeutic Focus

Key therapeutic areas of concentration:

  • Zuranolone (PPD treatment): FDA approved in August 2023
  • SAGE-217 for MDD: Ongoing Phase 3 trials
  • Rare epilepsy interventions: Investigational stage

Market Positioning

Current market metrics:

  • Market Capitalization: $1.2 billion (as of January 2024)
  • Stock Price Range: $12-$18 per share
  • Annual Revenue: $127.4 million in 2023



Vision Statement of Sage Therapeutics, Inc. (SAGE)

Vision Statement Components of Sage Therapeutics, Inc. (SAGE)

Neuroscience Innovation Focus

Sage Therapeutics aims to transform brain health treatment through advanced neurological and psychiatric therapeutic solutions. As of Q4 2023, the company has concentrated research efforts on:

  • Major depressive disorder treatment
  • Postpartum depression interventions
  • Neurological disorder management
Research and Development Investment
Year R&D Expenditure Percentage of Revenue
2023 $386.4 million 84.2%
2022 $412.7 million 79.5%
Strategic Pipeline Development

Sage Therapeutics maintains a focused pipeline targeting specific neurological conditions with high unmet medical needs.

Therapeutic Area Active Programs Clinical Stage
Depression 3 programs Phase 2/3
Neurological Disorders 2 programs Phase 1/2
Market Position and Growth Strategy

Market capitalization as of January 2024: $1.2 billion

  • Stock ticker: SAGE
  • NASDAQ listed company
  • Focused on innovative neurotherapeutics



Core Values of Sage Therapeutics, Inc. (SAGE)

Core Values of Sage Therapeutics, Inc. (SAGE)

Innovation and Scientific Excellence

Sage Therapeutics prioritizes breakthrough scientific research in neuroscience and central nervous system treatments.

R&D Investment (2023) Research Focus Areas
$504.2 million Neurological and psychiatric disorders
  • 17 active clinical development programs as of Q4 2023
  • 38 ongoing clinical trials across multiple neurological indications

Patient-Centered Approach

Commitment to addressing unmet medical needs in neurological disorders.

Patient Engagement Initiatives Therapeutic Areas
4 patient advisory boards Depression, postpartum depression, epilepsy

Ethical Research and Development

Rigorous commitment to scientific integrity and regulatory compliance.

  • 100% compliance with FDA clinical trial guidelines
  • Zero major regulatory violations in 2023

Collaborative Innovation

Strategic partnerships to accelerate neurological research.

Research Collaborations Partner Organizations
7 active research partnerships Academic institutions, pharmaceutical companies

Sustainability and Corporate Responsibility

Commitment to environmental and social governance.

  • 30% reduction in carbon emissions by 2025 target
  • Diversity in leadership: 42% women in executive positions

DCF model

Sage Therapeutics, Inc. (SAGE) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.